Sinopharm’s EUA application now under FDA review
MANILA, Philippines — China state-owned firm Sinopharm has applied for its Covid-19 vaccine’s emergency use authorization (EUA) in the Philippines, the Food and Drug Administration (FDA) confirmed Tuesday.
FDA Director General Eric Domingo said they are in the process of reviewing Sinopharm’s documents.
“An online application was filed yesterday afternoon and the FDA is checking the contents of the submission now,” Domingo told INQUIRER.net in a text message.
Roque has said Sinopharm’s vaccine is the one preferred by President Rodrigo Duterte. It was also endorsed by Duterte’s special envoy to China Ramon Tulfo, who had recently admitted to having received vaccine jobs in October, along with other unnamed Cabinet officials.
The FDA has so far given an EUA to only three vaccines developed by Pfizer-BioNTech, AstraZeneca and Sinovac.
Meanwhile, the EUA application of India’s Bharat Biotech and Russia’s Gamaleya Research Institute remain under evaluation.